STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #434 by analyst upside · 2026-06-27
OTLK
Outlook Therapeutics, Inc.
Healthcare · Market Cap $254M · P/E 0x
ANALYST PRICE TARGET
+221.6%
implied upside to consensus target
Current Price $1.71
Consensus Target $5.5
Bull Target $10.0
Bear Target $0.5
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
1
Sell
0
52-Week Low $0.16
52-Week High $3.39
YTD Return +159.1%
FUNDAMENTALS
Market Cap $254M
P/E Ratio (TTM) N/A
Forward P/E -7.8x
EPS (TTM) $-1.13
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.16
52-Week High $3.39
Current Price $1.71
Bear Target $0.5
Bull Target $10.0
● Now $1.71 ● Target $5.5
TRADING DATA
Avg Volume 18.5M
YTD Return +159.1%
Analyst Count 3
Consensus Buy
Upside to Target +221.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Outlook Therapeutics, Inc. (OTLK) is currently trading at $1.71 with a Wall Street consensus price target of $5.5, implying potential upside of 221.6% over the next 12 months. 3 analysts currently cover OTLK, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $0.5.

OTLK operates in the Healthcare sector with a market capitalisation of $254M. The stock is up 159.1% year-to-date and is currently trading near the lower end of its 52-week range of $0.16 – $3.39.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OTLK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital — Reiterated
Buy → Buy 2026-06-11 Building track record
BTIG ↓ Downgrade
Buy → Neutral 2026-05-18 38% win rate (8 calls)
Ascendiant Capital — Reiterated
Buy → Buy 2026-03-11 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2026-02-18 31% win rate (48 calls)
Chardan Capital — Reiterated
Neutral → Neutral 2026-02-18 33% win rate (6 calls)
Chardan Capital — Reiterated
Neutral → Neutral 2026-01-05 33% win rate (6 calls)
HC Wainwright & Co. — Reiterated
Neutral → Neutral 2026-01-02 31% win rate (48 calls)
Ascendiant Capital — Reiterated
Buy → Buy 2025-12-22 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →